This article was originally posted on July 30.
454 Life Sciencs and Roche NimbleGen said last week that they are collaborating with Eli Lilly and SeqWright to study several psychiatric diseases by selective genome sequencing.
The goal of the project is to identify genetic variants that are potentially associated with a number of unspecified psychiatric illnesses.
Under the collaboration, SeqWright, a sequencing service provider based in Houston, will use NimbleGen's sequence capture technology and 454's sequencing platform to selectively enrich and sequence approximately 40 megabases of the human genome.
"We are participating in this collaboration as a way to better examine the root causes of various psychiatric diseases," Brian Edmonds, research advisor for global external research and development at Lilly, said in a statement. "If this project delivers as expected, we hope to identify new biomarkers or novel drug targets for future development of medicines to treat any array of psychiatric illnesses."
This is not SeqWright's first partnership on a clinical project that involves the NimbleGen and 454 technologies. In June, the firm said it was collaborating with Roche Applied Science (the Roche business that houses both NimbleGen and 454) and the University of Miami Miller School of Medicine to study genetic variants associated with dilated cardiomyopathy by sequencing 180,000 exons from samples of patients.
Earlier this year, Roche NimbleGen said it was offering its sequence capture services through a partnership with SeqWright.